Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Overview of attention for article published in New England Journal of Medicine, December 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 10 news outlets
blogs: 4 blogs
policy: 3 policy sources
twitter: 62 X users
patent: 71 patents
facebook: 4 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
f1000: 1 research highlight platform
guideline: 7 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 5 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 67 X posts from 62 X users, with an upper bound of 1,914,210 followers.

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2012) "At the interim analysis, median progression-free survival was 6.9 months with everolimus plus exemestane and 2.8 months with placebo plus exemestane..." https://t.co/…

RT @dawood_findakly: @JasmineSukumar @TumorBoardTues @Dr_RShatsky @PTarantinoMD @hoperugo @NicoleKuderer @StoverLab @CarmenCalfa @sardesai_…

@JasmineSukumar @TumorBoardTues @Dr_RShatsky @PTarantinoMD @hoperugo @NicoleKuderer @StoverLab @CarmenCalfa @sardesai_sagar @stolaney1 @OncoAlert @JavierCortesMD @DrHBurstein @drenriquegrande @RICKLIN4TH @ProfWishart @ProfAMThompson @oncoplastics @Liz_O…

RT @aftimosp: Everolimus (+exemestane) had received regulatory approval for the treatment of HR+/HER2- metastatic #BreastCancer after progr…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 63 additional X posts.